18:30 , Jan 11, 2019 |  BC Week In Review  |  Company News

Former Insys CEO pleads guilty to opioid prescription kickbacks

Michael Babich, former president and CEO of Insys Therapeutics Inc. (NASDAQ:INSY), pleaded guilty on Jan. 9 in conspiring to bribe physicians to unnecessarily prescribe Subsys fentanyl sublingual spray and defraud insurance companies. The opioid is...
18:32 , Aug 10, 2018 |  BC Week In Review  |  Company News

FDA reviewers say data are lacking on TIRF drug use

FDA reviewers pointed to significant data gaps for evaluating the REMS program for transmucosal immediate-release fentanyl (TIRF) drugs at a joint advisory committee meeting Aug. 3. Participants gave "important feedback" that insufficient data exists to...
07:16 , Jul 29, 2017 |  BioCentury  |  Finance

Show us your shorts

Absent any data showing a sustained impact of manipulative short selling on biotech valuations or their ability to raise capital, it is difficult to discern what direct benefit biotech companies would gain from BIO ’s...
07:00 , Apr 25, 2016 |  BioCentury  |  Politics, Policy & Law

SCOTUS to the rescue?

The U.S. Supreme Court will hear arguments on Monday in a case that could either overturn or reinforce policies that unfairly tilt the inter partes review system against patent holders, according to life sciences companies....
07:00 , Mar 21, 2016 |  BC Week In Review  |  Company News

Acorda, Amgen, Insys, Pfizer, Roche, Hayman Capital Management autoimmune news

The U.S. Patent Trial and Appeal Board instituted inter partes (IPR) review petitions from hedge fund manager Kyle Bass against four of the five patents covering Acorda’s Ampyra dalfampridine for multiple sclerosis. If all of...
01:47 , Mar 12, 2016 |  BC Extra  |  Company News

PTAB institutes Bass' Ampyra IPRs, denies others

The U.S. Patent Trial and Appeal Board instituted inter partes (IPR) review petitions from Kyle Bass' Coalition for Affordable Drugs against four of the five patents covering multiple sclerosis drug Ampyra dalfampridine from Acorda Therapeutics...
07:00 , Sep 14, 2015 |  BioCentury  |  Politics, Policy & Law

IPR battles

A bipartisan backlash against the pricing of specialty drugs has eroded the biopharma industry's political support, leading members of Congress to question whether efforts to exempt drug patents from the inter partes review system would...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

Insys, Hayman Capital Management neurology news

Hedge fund manager Kyle Bass filed three new inter partes review (IPR) petitions with the Patent Trials and Appeals Board (PTAB) of the U.S. Patent and Trademark Office challenging three patents from Insys that cover...
02:05 , Aug 26, 2015 |  BC Extra  |  Company News

Insys' Subsys becomes Bass' latest target

Kyle Bass' Coalition for Affordable Drugs XI filed three new inter partes review (IPR) petitions with the Patent Trials and Appeals Board (PTAB) of the U.S. Patent and Trademark Office challenging three patents from Insys...
07:00 , Aug 11, 2014 |  BioCentury  |  Strategy

Profusion of exclusions

Express Scripts Holding Co. 's 2015 formulary exclusions offer hope that companies can renegotiate once-excluded drugs back into coverage. But the pharmacy benefits manager appears to be expanding the number of drugs and drug classes...